Disclosure: This site may earn affiliate commissions when you click provider links. This doesn't affect our recommendations. Learn more
Found vs Noom Med compared: real monthly cost, compounded and brand-name GLP-1s, coaching, insurance help, and which program fits your situation.
Found and Noom Med look alike at first glance. Both prescribe GLP-1 medications online, both sell bundled compounded plans, and both pitch themselves as more than a prescription. But they're built around different strengths. Noom Med starts from Noom's behavior-change app and adds medication, with human 1:1 coaching included. Found starts from clinical care and insurance: it's in-network with many insurers, prescribes a wider catalog, and gets cheap only when you prepay. If you're searching "Noom GLP-1" or "Noom Med cost" and wondering how Found stacks up, the short answer is this: Noom fits people who want coaching and no long prepay. Found fits people with insurance, or people willing to commit to 6 to 12 months for a lower price.
Last verified: October 28, 2026 by RxPickr Editorial Team. We re-checked both providers' pricing and plan pages on their own websites the day this article was published. Prices may change, so confirm at checkout. Our methodology is at How we rate providers.
Answer 10 questions and get a personalized recommendation.
Question 1 of 10
Do you have insurance that may cover GLP-1 medications?
Free, about a minute. Your answers stay in your browser.
| Found | Noom Med | |
|---|---|---|
| Compounded semaglutide | $169/mo (12-month prepaid); $219 (6-month), $249 (3-month), $289 month to month | $129 first 4 weeks, then $249/mo, billed quarterly |
| Compounded tirzepatide | $239/mo (12-month prepaid); $289 (6-month), $309 (3-month), $359 month to month | $149 first 4 weeks, then $299/mo, billed quarterly |
| Microdose plan | Yes (compounded semaglutide); no separate published price | $79 to start, then $179/mo |
| Brand-name program fee | $149/mo month to month, $99/mo on a 12-month plan, medication extra | $39 first month, then $129/mo billed quarterly, medication extra |
| Brand-name drugs listed | Wegovy (pen and pill), Zepbound, Foundayo, Ozempic, Mounjaro, Saxenda, Victoza and more | Wegovy (pen and pill), Zepbound, Foundayo, Ozempic, Mounjaro, generic liraglutide, metformin |
| Insurance | Bills visits to many insurers; compounded semaglutide plan from $99/mo with insurance (12-month), plus visit copays | Helps check brand-name drug coverage; insurance does not cover the Noom program |
| Coaching | Clinician check-ins, AI companion, member community | 1:1 coaching, daily lessons, full Noom app, community |
| Billing | Per 28-day cycle; 1, 3, 6 or 12-month terms | Quarterly (12-week) subscription |
| Best for | Insured patients, 6- to 12-month prepayers | Coaching-first patients, microdose starters, no prepay |
Sources: Found plans and pricing, Found compounded semaglutide, Found compounded tirzepatide, Noom Med pricing, Noom Microdose, Noom Med, all checked October 28, 2026.
Here's where most "Noom monthly cost" searches go wrong: the advertised number is the first month. Both providers discount it.
Noom's three compounded plans each have a starter price for the first four-week supply, then a higher ongoing rate. Per Noom's pricing page:
Each of these is all-inclusive: clinical care, medication and the digital program. Billing is quarterly, so each charge covers a 12-week block rather than a single month. Noom's microdose page says you can cancel anytime; check what happens to an unused part of a quarter before you sign up.
For brand-name medication, Noom charges a program fee of $39 for the first month, then $129/month, and says plainly that the medication isn't included (Noom Wegovy page). If you pay cash for Zepbound, Noom says members can get vials through LillyDirect from $299/month (Noom Zepbound page).
Found's compounded plan is one price that covers medication, clinical care and membership, and it's the same at every dose. Tirzepatide costs more than semaglutide, and what changes the price most is how long you commit. Per Found's compounded semaglutide and compounded tirzepatide pages, checked October 28, 2026, the cash-pay rates per 28-day cycle are:
| Found cash-pay term | Semaglutide | Tirzepatide |
|---|---|---|
| Month to month | $289 ($179 for the first cycle) | $359 ($219 for the first cycle) |
| 3 months | $249 | $309 |
| 6 months | $219 | $289 |
| 12 months, paid up front | $169 | $239 |
Two details matter. The 12-month price assumes you pay for the year up front (Found pricing), so the day-one charge is large. And Found bills every 28 days, which adds up to 13 charges a year instead of 12. Found was also advertising up to $100 off the first checkout when we looked, so the real first-cycle price can be lower than the table shows.
For brand-name medication, Found charges a membership of $149/month month to month or $99/month on a 12-month plan, and you pay for the drug separately at the manufacturer's self-pay price (Found Wegovy pill page). Foundayo starts at $149/month for the medication alone, per Found's Foundayo page.
On compounded semaglutide with no long commitment, Noom is cheaper: $249/month against Found's $289. Noom's quarterly billing roughly matches Found's 3-month term, and there the two tie at $249. Found pulls ahead only on its 6-month and 12-month plans.
Tirzepatide follows the same pattern. Noom charges $299/month, billed quarterly. Found charges $359 month to month and $309 on 3 months, both more than Noom, and drops below Noom only on its 6-month ($289) and 12-month plans ($239).
On brand-name drugs, the medication price is the manufacturer's either way, so the program fee decides it. On Noom's quarterly billing, its $129/month fee is lower than Found's month-to-month $149. Prepay a year with Found and its $99 is lowest.
Neither is the cheapest compounded option we track. If price is the only thing that matters, see our Eden vs Found comparison and the cheapest semaglutide online roundup.
Both programs offer compounded semaglutide and compounded tirzepatide. Compounded medications contain the same active ingredients as Wegovy and Zepbound but are not FDA-approved as finished products, and the FDA has not reviewed them for safety, effectiveness or quality (FDA). Both providers say as much in their own fine print. Our guide to whether compounded semaglutide is safe covers the tradeoffs.
The brand-name versions were tested in large randomized trials: semaglutide 2.4 mg (Wegovy) in STEP 1 (NEJM, 2021) and tirzepatide (Zepbound) in SURMOUNT-1 (NEJM, 2022).
Found's catalog is wider. Its pricing page lists compounded semaglutide and tirzepatide alongside Ozempic, Wegovy, Zepbound, Mounjaro, Saxenda, Foundayo and Victoza, and its site also lists non-GLP-1 options such as Contrave, metformin and topiramate (Found). Found's offer terms also list compounded liraglutide, a daily injection, without a published price.
Noom's lineup is closer than you might expect. Its Med page lists Wegovy (pen and pill), Zepbound, Ozempic, Mounjaro, Foundayo, generic liraglutide and metformin, plus its own compounded programs (Noom Med). Noom notes that metformin isn't FDA-approved for weight loss. If you want an oral option, both list the Wegovy pill and Foundayo; see Foundayo vs the Wegovy pill.
Noom has the more developed microdose offer, with its own plan and a published price. Found has a microdosing program built on compounded semaglutide, but no separate published price.
Be realistic about what microdosing is. The weight-loss results quoted for these drugs come from trials of full maintenance doses, and in SURMOUNT-1 the effect was larger at higher tirzepatide doses (NEJM, 2022). No large trial has tested microdosing as these programs sell it. Our GLP-1 microdosing guide goes deeper.
This is Noom's clearest advantage, and it isn't close.
Every Noom Med plan includes Noom's full behavior-change program and 1:1 coaching, per Noom's pricing FAQ. That means daily psychology-based lessons, food and water logging, "human coaching with AI-powered support," and a member community. Noom also cites an internal analysis in which members who opened the app more often lost more weight on a GLP-1 (Noom Med pricing), though Noom itself notes the association does not imply causation.
Found's support is more clinical. Its program page describes monthly provider check-ins, prescription adjustments, personalized plans, a members-only community and 24/7 on-demand support. Between visits you can message Aimee, Found's AI companion. Cash-pay care is mostly text-based; insurance members have video visits. Our earlier coverage described Found health coaches, but we couldn't find human health coaching on Found's current plan pages in October 2026.
Does coaching matter? In STEP 1, the trial behind Wegovy, both the semaglutide and placebo groups also received a lifestyle intervention (NEJM, 2021), so its results describe medication plus lifestyle change, not the drug alone. How much an app-based coaching program adds hasn't been tested in an equivalent trial. Still, if past attempts fell apart without accountability, Noom's program is designed around that kind of support.
Pros
Cons
Found is set up to use insurance; Noom's program isn't. Found bills its clinician visits to insurance, and Found says more than 100 million Americans have in-network coverage with it, even if their plan doesn't cover brand-name GLP-1s (Found). Found also says insurance doesn't cover its subscription fee itself (Found insurance), but insured members pay a lower plan price: compounded semaglutide is $199/month month to month or $99/month on a 12-month plan, and compounded tirzepatide $289 or $179, plus required video visits billed at your copay, typically around $30 (checked October 28, 2026). Its insurance page lists accepted states, and not every state is on it. For brand-name drugs, Found helps with coverage and prior authorization.
Noom also helps with brand-name drug coverage. Its FAQ says the telehealth program can work with your insurance to check for coverage, with the medication billed to insurance if approved. But insurance doesn't cover the Noom program itself (Noom Med pricing).
Both providers say many of their plans may be HSA or FSA eligible. Our HSA and FSA guide explains what to check, and the GLP-1 insurance coverage guide covers prior authorization.
Found
From $169/mo (12-month compounded plan, medication included)
Bills visits to many insurers, and has the lowest compounded prices in this comparison on a 6- or 12-month prepay.
Both programs start with an online health assessment reviewed by a licensed clinician, and both prescribe only when the clinician finds it appropriate. Found says its clinician review takes one to two days and that most members can start within a week (Found program). Noom says if prescribed, its medications ship within about seven days (Noom Med).
Noom's brand-name medication pages list a lab step ("Understand your health with labs") in the onboarding (Noom Wegovy page). Its compounded program pages don't spell out a lab requirement. Found's current pricing and program pages don't describe lab requirements or fees; our Found review noted labs billed separately. Ask about labs and any fees before you pay, on either platform.
Neither provider is available everywhere. Noom says its programs aren't available in all 50 states, and Found says prescriptions aren't available in all states either.
Pick Noom Med if:
Pick Found if:
This isn't a case where one provider is better across the board. Noom Med is the better choice for people who want coaching, a low-dose start, or no long prepay. Its behavioral program is the real product, and the medication fits around it. Found is the better choice for insured patients and for anyone willing to prepay 6 to 12 months, for semaglutide or tirzepatide.
If you're uninsured and want the lowest price with no coaching, neither may be your best pick. Read our Found review for the full breakdown, or take the RxPickr GLP-1 quiz to compare against every provider we track. Whichever you choose, GLP-1 medications require a prescription, so go over your health history and goals with a licensed healthcare provider before starting.